STARRT

STARRT™

Obstetrics A falloposcopy system, Selective Tubal Assessment to Refine Reproductive Therapy designed for visualizing fallopian tubes to diagnose proximal tubal occlusion. See Falloscopy.
References in periodicals archive ?
As the Safety Week was not just about the workers, the STARRT talks undertaken during the week were reviewed and prizes awarded to the supervisors who did them well.
Driving home the message of safety at work
The Company has developed the STARRT Falloposcopy and T-TAC catheter systems to improve the diagnosis and treatment of fallopian tube diseases and disorders, a primary cause of infertility.
Conceptus Reports First Quarter 1999 Financial and Operational Results; Reports Results From Phase II Study of S/TOP Transcervical Permanent Contraception Device
During the quarter, Conceptus received clearance of a 510(k) from the United States Food and Drug Administration (FDA) for the Stargate(tm) catheter, a component of the Company's STARRT Falloposcopy System.
Conceptus Announces 1Q98 Financial Results
In the near term, our T-TAC and STARRT systems will enable physicians in Japan to more accurately diagnose and prescribe treatments for couples seeking assistance.
JMS will market Conceptus' platform technology known as the T-TAC System, as well as the STARRT Falloposcopy system for the improved diagnosis of fallopian tube disorders, which account for approximately 35% of female infertility.
Conceptus announces marketing and distribution agreement in Japan with JMS
Bacich will have responsibility for all of Conceptus's new product development projects, including the STARRT (Selective Tubal Assessment to Refine Reproductive Therapy) Falloposcopy system, the S/TOP (Selective Tubal Occlusion Procedure) permanent contraception system, and the Microgyn Resectoscope Safety Sheath system.
Conceptus Announces Management Changes
The agreement grants exclusive distribution rights to Conceptus' STARRT Falloposcopy system in Singapore, Malaysia and Thailand.
Progress was reported in the STARRT (Selective Tubal Assessment to Refine Reproductive Therapy) Falloposcopy system development project.
Conceptus Reports First Quarter 1997 Financial and Operational Results
In November, at the annual meeting of the American Society of Reproductive Medicine, results were presented from the International Multicenter Study of Falloposcopy (IMSF), a clinical study of Conceptus's STARRT (Selective Tubal Assessment to Refine Reproductive Therapy) Falloposcopy System at twenty-two centers in Europe and Australia.
Conceptus Reports Fourth Quarter and Year 1996 Financial Results
NASDAQ:CPTS) announced today that it has received clearance from the United States Food and Drug Administration (FDA) to market its STARRT Falloposcopy System for diagnosis of proximal tubal occlusion (PTO), a blockage of the fallopian tube which is a known cause of infertility.
Conceptus' STARRT Falloposcopy System Receives U.S. FDA Marketing Clearance for Diagnosis of Proximal Tubal Occlusion
Food and Drug Administration (FDA) that its 510(k) submission for a diagnostic application of its STARRT System is the correct regulatory approach and that the agency will not require additional clinical trials.
Conceptus reports third quarter 1996 financial results
In July, Conceptus brought to trial in Europe and Australia the STARRT (Selective Tubal Assessment to Refine Reproductive Therapy) falloposcopy system which incorporates a newly developed distal tip, designed to facilitate improved imaging of the fallopian tube.
CONCEPTUS REPORTS SECOND QUARTER AND SIX MONTHS FINANCIAL RESULTS
Medical browser ?
Full browser ?